«NNA ESTABLISHED INNOVATIONS IN DIAGNOSTICS Cancer DiagnosticsIdentify clinically significant mutations in cancer-associated genes to optimize patient-specific therapy Modern cancer therapies target specific cell processes. The development of monoclonal antibodies binding to epidermal growth factor receptor (EGFR) and the development of drugs inhibiting EGFR tyrosine kinase have been major steps towards personalized cancer treatment. Targeted therapy generally causes less damage to healthy cells compared to conventional chemotherapy. Optimal results in cancer treatment are achieved when the personalized approach is chosen. Monoclonal antibody and tyrosine kinase inhibitor therapies work exceptionally well in many, but not in all cases. Treatment response is highly dependent on the genetic profile of the tumor. Thus, genetic tests identifying relevant mutations in oncogenes and tumor suppressor genes facilitate an efficient patient-specific therapy. ViennaLab StripAssays® and RealFast™ Assay • Simple protocol for complex diagnostic questions • Manual or automated processing • No expensive lab equipment • Ready-to-use reagents ^ • CE/IVD-labeled complete kits J

KRAS & NRAS KRAS and NRAS are members of the RAS oncoprotein family that act as mitogen-activated protein kinase (MAPK) signaling pathway GTPases downstream of the epidermal growth factor receptor (EGFR). Activating RAS mutations predict a lack of response to anti-EGFR monoclonal antibody therapies (cetuximab or panitumumab) in colorectal cancer (CRC) patients. KRAS and NRAS mutations are mutually exclusive. In the Panitumumab Randomized Trial in Combination with Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME) study, NRAS mutations were detected in a fraction of approximately...

Mutations covered by the EGFR XL StripAssay® and the EGFR T790M RealFast™ Assay Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancers. Somatic mutations in the epidermal growth factor receptor tyrosine kinase (EGFR-TK) domain influence the treatment with EGFR-TK inhibitors. First-line TK inhibitors, such as erlotinib and gefitinib, are effective anti-cancer drugs in NSCLC patients carrying activating EGFR mutations. Conversely, patients carrying the resistance mutation T790M do not benefit from first-line EGFR-TK inhibitor therapy. Identification of EGFR mutations...

»NNA ESTABLISHED INNOVATIONS IN DIAGNOSTICS ViennaLab StripAssays® and RealFast™ Assay identify the most relevant mutations to support therapy decisions for colorectal cancer, thyroid cancer, lung cancer, melanoma and other types of cancer. The three steps of the StripAssays® Hstep Order Information: PGX-5FU XL StripAssay®: BRAF 600/601 StripAssay®: NRAS XL StripAssay®: EGFR XL StripAssay®: 5-630 (20 tests/kit) KRAS XL StripAssay®: 5-680 (20 tests/kit) EGFR T790M RealFast™ Assay: 8-110 (100 rxn) EGFR T790M RealFast™ Assay: 8-113 (32 rxn) ViennaLab offers StripAssays® and RealFast™ Assays for...